Stephen P. Arneric, PhD
Dr. Stephen P. Arneric is a pharmaceutical scientist and leader with a proven track record in delivering differentiated therapeutics. His experience spans more than 25 years of large pharma (Abbott, Lilly, Pharmacia, & Pfizer), biotechnology (DuPont Pharmaceuticals, Neuromed Pharmaceuticals), and academic service (University of Iowa, Cornell Medical College, Southern Illinois University School of Medicine), resulting in over 30 drug candidates entering into clinical development to treat pain and psychiatric and urological disorders. He has led complex cross-functional matrix organizations of 100+ staff, and effectively managed $20MM budgets within target. His Phase 3 or Launched Product Development experience includes the following: Exalgo™ (Oros-hydromorphone for OA & CLBP), Esreboxetine (DPNP), Dynastat™ (acute pain), Lyrica™ (neuropathic pain), Cymbalta™ (musculoskeletal pain, fibromyalgia, DPNP), and Detrol™ (overactive bladder). Steve has leveraged global alliances devoted to enhancing cross-organizational strengths (Merck, Recordati, Covance, NeuroSearch, RaQualia, Jubilant, Noxxon, Arteus, PsychoGenics, AnaBios, Chorus, Scripps, University of Pittsburgh, University of Colorado, University of Geneva, ORCATECH, The University of Arizona, University of British Columbia, and others). Dr. Arneric is an accomplished author with 145 peer-reviewed articles, 190 abstracts, 17 chapters, one book, and numerous IND submissions, as well as a co-inventor of 15 patents. He is a professional with a high aptitude for strategic, critical, and tactical thinking that evaluates both scientific and business conditions resulting in effective solutions to challenges that impact diverse departments within an organization.